Table 5.

Comparative characteristics of patients at risk of  recurrence (because of the presence of nephrotic syndrome at baseline) treated with pre-emptive rituximab versus non-treated

Characteristics	Rituximab (n = 12)	Non-rituximab (n = 22)	P-value
At baseline
Age at diagnosis (years)	24.5 ± 18.5	30 ± 13.7	0.358
Gender (males), n/N (%)	7/12 (58.3)	14/22 (63.6)	0.761
Nephrotic syndrome, n/N (%)	12/12 (100)	22/22 (100)	1
Serum albumin at diagnosis (g/dL)	2.53 ± 0.85	2.40 ± 0.51	0.745
Proteinuria at diagnosis (g/24 h)	10.90 ± 4.74	6.81 ± 2.98	0.102
Immunosuppressive therapy, n/N (%)	8/12 (66.7)	14/22 (63.6)	0.985
Time from diagnosis to ESRD (years)	5.12 ± 4.44	7.58 ± 7.11	0.332
Duration of dialysis (years)	1.91 ± 1.26	2.27 ± 2.40	0.630
Previous transplantation, n/N (%)	2/12 (16.7)	5/22 (22.7)	0.521
Recurrence in previous allograft, n/N (%)	2/12 (16.7)	2/22 (9.1)	0.359
At transplantation
Age at transplantation (years)	35.0 ± 15.2	42.4 ± 12.2	0.130
BMI at transplantation (kg/m2)	21.6 ± 4.3	25.4 ± 3.5	0.050
Residual diuresis >500 mL, n/N (%)	6/12 (50)	6/22 (27.3)	0.350
Donor age (years)	39.8 ± 17.1	38.6 ± 14.8	0.831
Donor source, n/N (%)	–	–	0.239
Deceased	8/12 (66.7)	15/22 (68.2)	–
Living related	3/12 (25)	1/22 (4.5)	–
Living non-related	0/12 (0)	1/22 (4.5)	–
Non-heart-beating donor	1/12 (8.3)	5/22 (22.7)	–
Number of HLA mismatches	3.6 ± 1.2	3.7 ± 1.3	0.886
Cold ischaemia time (min)	922.3 ± 506.2	890.7 ± 405.6	0.849
Induction therapy, n/N (%)	8/12 (66.7)	14/22 (63.6)	0.860
Thymoglobulin	2/12 (16.7)	9/22 (40.9)	0.200
Basiliximab	6/12 (50)	5/22 (22.7)	–
Delayed graft function, n/N (%)	5/12 (41.7)	11/22 (50)	0.426
Acute rejection, n/N (%)	5/12 (41.7)	5/22 (22.7)	0.421

Values are presented as mean ± SD unless stated otherwise.